Alcohol and psoriasis: the causal claim is weaker than you have been told, and the treatment problem is bigger

The number everyone quotes

The headline finding comes from a dose-response meta-analysis that screened 3,904 studies and kept 48, covering 1,702,847 individuals across 24 countries. Drinking was positively associated with psoriasis, with an odds ratio of 1.47 and a confidence interval from 1.27 to 1.70 ^[1]. It also found a gradient rather than a cliff: each additional gram of daily alcohol raised the odds by about 4%, with the association most prominent above 45 g a day, which the authors put at 3.2 drink equivalents ^[1].

A gradient is usually the mark of a real biological effect, which is why this paper gets cited the way it does. But look at the subgroups and something odd appears. The association was significant in men, at an odds ratio of 1.84 with an interval from 1.13 to 3.01, and not significant in women, at 1.22 with an interval from 0.97 to 1.54 ^[1]. There is no mechanism anyone has proposed by which ethanol inflames male skin and spares female skin. What there is, in every drinking study ever run, is a difference in who drinks how much and who says so accurately.

That is the first hint that the thing being measured might not be the thing being claimed. Psoriasis is visible, it is stigmatising, it is strongly associated with depression, and the direction of the arrow between a distressing skin disease and a drink is not obvious from a cross-sectional questionnaire. Most of the studies in that pool cannot tell you which came first, and the meta-analysis is honest that its dose-response arm rests on eight studies, five of them case-control ^[1].

Sources for this section: [1] Dose-response analysis between alcohol consumption and psoriasis: A systematic review and meta-analysis

Ask the question with genetics and the answer changes

There is a way to break the tie. People inherit genetic variants that nudge how much they drink, and those variants are dealt out at conception, long before anyone has psoriasis, a job, a diagnosis or a reason to drink about it. If drinking causes psoriasis, then people carrying more drinking-prone variants should get more psoriasis. That comparison is called Mendelian randomization, and it is about as close to a randomised trial as this question will ever get, because nobody is going to allocate half a cohort to drink for twenty years.

It has been done, on alcohol and smoking together, using genome-wide data on 941,280 people for alcohol consumption and psoriasis data from 19,032 cases with 286,769 controls ^[2]. Smoking came through clearly: smoking initiation at an odds ratio of 1.46 with an interval from 1.32 to 1.60, and lifetime smoking at 1.96 with an interval from 1.41 to 2.73 ^[2]. Alcohol did not. The analysis found no causal relationship between alcohol consumption and psoriasis, at P = 0.379, and the reverse direction was not significant either ^[2].

Two studies, opposite conclusions, and the difference is not a contradiction: it is the design. The observational pool measures who drinks and who has psoriasis at the same moment, and everything that pushes both up at once, from smoking to weight to social disadvantage to the disease itself, lands inside the association. The genetic study is immune to nearly all of that. It is not immune to everything, and it has one real limitation worth naming: the genetic instruments track habitual consumption across a population, so a design like this is poorly suited to detecting harm concentrated in heavy or binge drinking specifically. What it does establish is that ordinary-volume drinking is not what put psoriasis on your skin.

That matters practically, because the causal story is the one people act on. Someone who stops drinking in the belief that alcohol caused the disease, and whose plaques are unchanged three months later, has been set up to conclude that nothing in their control makes any difference. The literature earned them that disappointment.

Sources for this section: [2] Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study · [1] Dose-response analysis between alcohol consumption and psoriasis: A systematic review and meta-analysis

Where alcohol stops being theoretical: how well treatment works

Causing a disease and interfering with its treatment are separate questions, and the second one has been studied directly. A prospective multicentre cohort followed 266 people starting systemic therapy for moderate-to-severe psoriasis, 134 on biologics and 132 on conventional systemics, and screened them for alcohol misuse with the CAGE questionnaire ^[3]. Across the whole cohort treatment worked well, with median PASI falling from 13 at baseline to 3 during follow-up ^[3].

A higher CAGE score was associated with a poorer response, at a regression coefficient of 1.40 with a confidence interval from 0.04 to 2.77 ^[3]. That lower bound is almost touching zero, and it deserves saying plainly: this is a real but modest finding from a single cohort, not a law. Put it next to the other predictors in the same model and the ordering is instructive. Obesity carried 1.84, and being on a conventional systemic rather than a biologic carried 4.39, with an interval from 2.84 to 5.95 ^[3]. Which drug you are on dominates. Alcohol is a smaller term in the same equation, sitting alongside weight.

This is also the finding most likely to be mechanistically boring in the best way. CAGE screens for problem drinking, not for a glass of wine, and problem drinking is entangled with whether the tablets get taken and the appointments get kept. Whether alcohol blunts the drug or blunts adherence, the practical consequence for the person in the chair is identical, and it is the one thing in this literature that is directly actionable while treatment is underway.

Sources for this section: [3] Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

And the liver, if you are on methotrexate

Methotrexate is ordinary treatment for moderate-to-severe psoriasis, and the standard advice about alcohol on it has always been vague, delivered as a warning without a number. There is a number. A Danish population study compared people receiving methotrexate for psoriasis, psoriatic arthritis and rheumatoid arthritis: 5687, 6520 and 28,030 patients respectively ^[4]. Liver disease was commonest in the psoriasis group and least common in rheumatoid arthritis, and after adjusting for demographics, smoking, alcohol use, comorbidities and methotrexate dose, psoriasis patients were 1.6 to 3.4 times more likely to develop at least one liver outcome than rheumatoid arthritis patients on the same drug ^[4].

Read that adjustment carefully, because it is the whole point. The excess is not explained by psoriasis patients drinking more, since drinking was adjusted for. Something about psoriatic disease itself, most likely the metabolic and fatty-liver load that travels with it, leaves the organ with less headroom before methotrexate is prescribed. The authors' own conclusion is that monitoring should be more conservative in this group ^[4].

So the alcohol question changes shape entirely depending on which sentence you are in. As a cause of psoriasis, it looks like a confounded association. As an additional load on the liver of someone with psoriatic disease taking a hepatotoxic drug, it is being added to a baseline that is already measurably higher than the comparison group's. That is a specific fact about a specific situation, and it is worth more than a general instruction to cut down.

It is a conversation to have with whoever prescribes it, because they hold the monitoring bloods and the dose. What this evidence supplies is the reason the conversation is worth initiating rather than waiting for.

Sources for this section: [4] Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study

What this looks like on a Friday night

Nothing here supports abstinence as a psoriasis treatment, and this site is not going to pretend otherwise. The causal evidence points the other way, and the treatment evidence is about problem drinking rather than about a beer. Anyone selling a dry month as a plaque cure is selling something the data does not contain.

What the evidence does support is unremarkable and worth stating anyway. Australian guidance is no more than 10 standard drinks a week and no more than 4 on any one day, where a standard drink is 10 grams of pure alcohol ^[5]. Set that beside the meta-analysis, whose association concentrated above 45 g a day ^[1] — that is four and a half standard drinks every day, more than three times the weekly figure. The drinking level at which the psoriasis literature starts registering anything is well past the level at which general Australian guidance has already asked you to stop, for reasons that have nothing to do with skin.

There is one more link worth drawing, and it is the reason this essay sits where it does on the site. Alcohol is energy-dense and it is drunk on top of meals rather than instead of them, and weight is the lifestyle factor in psoriasis with the strongest evidence behind it ^[6]. Psoriasis also carries a raised cardiovascular risk that its dietary advice ought to be built around ^[7]. Both of those give a reason to look at what is in the glass that survives the collapse of the causal story, and neither requires believing that alcohol caused anything.

The practical upshot is small enough to hold in one hand. If you drink at ordinary levels, this is not the lever, and hunting for a flare trigger in your glass will cost you attention better spent on treatment and on weight. If you drink heavily and you are on systemic therapy, the evidence says your treatment is likely to work less well. If you are on methotrexate, the liver arithmetic is genuinely different for you than for the person next to you in the waiting room with rheumatoid arthritis, and that is worth raising at the next monitoring blood test rather than after it.

Sources for this section: [5] Australian Guidelines to Reduce Health Risks from Drinking Alcohol · [1] Dose-response analysis between alcohol consumption and psoriasis: A systematic review and meta-analysis · [6] Impact of weight-loss interventions on psoriasis severity: systematic review and meta-analysis · [7] Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network